Gomperts E D, de Biasi R, De Vreker R
Baxter Healthcare Corporation, Hyland Division, Glendale, CA 91203.
Transfus Med Rev. 1992 Jan;6(1):44-54. doi: 10.1016/s0887-7963(92)70155-2.
All reported studies to date, whether comparative or not, have shown a tendency toward a slower decrease in CD4+ numbers in patients receiving very high-purity agents with the rapidity in fall-off being affected by level of CD4+ numbers (low CD4+ numbers decreasing more rapidly), age (older persons showing more rapid CD4+ cell fall-off), and anti-HIV therapy. Clearly, these observations need to be extended in numbers, and the high-purity agents should also be similarly compared with the very high-purity therapies.
迄今为止，所有已报道的研究，无论是否具有对比性，均显示接受极高纯度药物的患者CD4+细胞数量下降趋势较为缓慢，其下降速度受CD4+细胞数量水平（CD4+细胞数量低者下降更快）、年龄（年长者CD4+细胞下降更快）以及抗HIV治疗的影响。显然，这些观察结果需要在数量上进一步扩展，并且高纯度药物也应与极高纯度治疗方法进行类似的比较。
